Compared with ND, the transcript levels of ITGA9 indicated significant low expression in bladder cancer, brain and central nervous system cancer, breast cancer, leukemia, liver cancer, lung cancer and etc., suggesting that the down-regulation of ITGA9 was common in various types of cancer (Fig. 9a). This evidence concerns the gene ITGA9 and central nervous system cancer.